Terms ending in 2030
Every in-force patent on Actelion Pharmaceuticals Ltd's record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,251,867 | Dosing Regimen for a Selective S1P1 Receptor Agonist In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence | |
| US 8,288,385 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-Phenyl-PYRIMIDINES In force · High confidence | Viatris Asia Pacific Pte. Ltd. | In force | High confidence | |
| US 10,660,880 | Dosing Regimen for a Selective S1P1 Agonist In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence | |
| US 8,809,334 | Therapeutic Compositions Containing Macitentan In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence | |
| US 8,785,484 | Dosing Regimen for a Selective S1P1 Receptor Agonist In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence | |
| US 8,658,675 | PYRIDIN-4-YL Derivatives In force · High confidence | Viatris Asia Pacific Pte. Ltd. | In force | High confidence | |
| US 9,133,179 | 2-Methoxy-PYRIDIN-4-YL-DERIVATIVES In force · High confidence | Viatris Asia Pacific Pte. Ltd. | In force | High confidence | |
| US 8,664,203 | Thiazole Derivatives and Their Use as P2Y12 Receptor Antagonists In force · High confidence | Viatris Asia Pacific Pte. Ltd. | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Actelion Pharmaceuticals Ltd.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.